Drug Development Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X

January’s top stories: Pfizer’s lung cancer drug fails two trials and first patients dosed with ADXS-HPV

Pfizer's lung cancer drug dacomitinib fails in two Phase III trials, while Advaxis doses first patient with ADXS-HPV in Phase I/II head and neck cancer trial. Drugdevelopment-technology.com wraps-up the key headlines from January 2014.

Go Top